MA34212B1 - Composés hétérocycliques et leurs utilisations - Google Patents

Composés hétérocycliques et leurs utilisations

Info

Publication number
MA34212B1
MA34212B1 MA35338A MA35338A MA34212B1 MA 34212 B1 MA34212 B1 MA 34212B1 MA 35338 A MA35338 A MA 35338A MA 35338 A MA35338 A MA 35338A MA 34212 B1 MA34212 B1 MA 34212B1
Authority
MA
Morocco
Prior art keywords
inflammatory
acute
disorders
diseases
limited
Prior art date
Application number
MA35338A
Other languages
English (en)
Inventor
Timothy D Cushing
Jason A Duquette
Xiao He
Julia Winslow Lohman
Youngsook Shin
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA34212B1 publication Critical patent/MA34212B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des hétéroaryles bicycliques substitués et des compositions contenant ceux-ci, pour le traitement de l'inflammation générale, de l'arthrite, de maladies rhumatismales, de l'arthrose, de troubles intestinaux inflammatoires, de troubles ophtalmiques inflammatoires, de troubles inflammatoires ou instables de la vessie, du psoriasis, de troubles de la peau avec des composantes inflammatoires, d'affections inflammatoires chroniques, comprenant mais non restreintes à des maladies auto-immunes telles que le lupus érythémateux disséminé (SLE), la myasténie gravis, la polyarthrite rhumatoïde, l'encéphalomyélite disséminée aiguë, le purpura thrombocytopénique idiopathique, la sclérose en plaques, le syndrome de Sjögren et l'anémie hémolytique auto-immune, des affections allergiques comprenant toutes les formes d'hypersensibilité. La présente invention concerne en outre des procédés pour traiter des cancers qui sont médiés, dépendants de ou associés à l'activité p110, comprenant mais non restreints à des leucémies, telles que la leucémie myéloïde aiguë (LMA), le syndrome myélodysplasique (SMD), des maladies myéloprolifératives (MPD), la leucémie myéloïde chronique (LMC), la leucémie lymphoblastique T aiguë (LLA-T), la leucémie lymphoblastique B aiguë (LLA-B), le lymphome non hodgkinien (LNH), le lymphome B et des tumeurs solides, telles que le cancer du sein.
MA35338A 2010-04-02 2011-04-01 Composés hétérocycliques et leurs utilisations MA34212B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32037810P 2010-04-02 2010-04-02
PCT/US2011/030888 WO2011123751A2 (fr) 2010-04-02 2011-04-01 Composés hétérocycliques et leurs utilisations

Publications (1)

Publication Number Publication Date
MA34212B1 true MA34212B1 (fr) 2013-05-02

Family

ID=43982368

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35338A MA34212B1 (fr) 2010-04-02 2011-04-01 Composés hétérocycliques et leurs utilisations

Country Status (25)

Country Link
US (1) US8575183B2 (fr)
EP (1) EP2552908A2 (fr)
JP (1) JP2013540099A (fr)
KR (1) KR20130103309A (fr)
CN (1) CN103221403A (fr)
AR (1) AR081448A1 (fr)
AU (1) AU2011235031B2 (fr)
BR (1) BR112012025164A2 (fr)
CA (1) CA2793897A1 (fr)
CL (1) CL2012002769A1 (fr)
CO (1) CO6630161A2 (fr)
CR (1) CR20120562A (fr)
EA (1) EA201291005A1 (fr)
IL (1) IL222288A0 (fr)
MA (1) MA34212B1 (fr)
MX (1) MX2012011387A (fr)
MY (1) MY184620A (fr)
PE (1) PE20130339A1 (fr)
PH (1) PH12012501922A1 (fr)
SG (1) SG184354A1 (fr)
TN (1) TN2012000449A1 (fr)
TW (1) TW201202219A (fr)
UY (1) UY33304A (fr)
WO (1) WO2011123751A2 (fr)
ZA (1) ZA201207341B (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2845856A1 (fr) 2009-06-29 2015-03-11 Incyte Corporation Pyrimidinones en tant qu'inhibiteurs de PI3K
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
EP2558463A1 (fr) 2010-04-14 2013-02-20 Incyte Corporation Dérivés condensés en tant qu'inhibiteurs de i3
WO2011163195A1 (fr) 2010-06-21 2011-12-29 Incyte Corporation Dérivés condensés de pyrrole en tant qu'inhibiteurs de pi3k
AU2011343712B2 (en) 2010-12-16 2015-09-17 Genentech, Inc. Tricyclic PI3k inhibitor compounds and methods of use
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
RU2013138835A (ru) * 2011-02-09 2015-03-20 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения в качестве ингибиторов pi3 киназы
WO2012125629A1 (fr) 2011-03-14 2012-09-20 Incyte Corporation Dérivés diamino-pyrimidines et diamino-pyridines substituées en tant qu'inhibiteurs de pi3k
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
EA031153B1 (ru) 2011-06-10 2018-11-30 Мерк Патент Гмбх Применение пиримидиновых соединений с btk ингибирующей активностью
UA121539C2 (uk) 2011-09-02 2020-06-25 Інсайт Холдинґс Корпорейшн Гетероцикліламіни як інгібітори рі3к
JP6117235B2 (ja) 2011-12-15 2017-04-19 ノバルティス アーゲー Ｐｉ３ｋの活性または機能の阻害剤の使用
US9493464B2 (en) * 2012-02-29 2016-11-15 The Scripps Research Institute Wee1 degradation inhibitors
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US9309243B2 (en) 2012-07-13 2016-04-12 Ucb Biopharma Sprl Imidazopyridine derivatives as modulators of TNF activity
WO2014072937A1 (fr) 2012-11-08 2014-05-15 Rhizen Pharmaceuticals Sa Compositions pharmaceutiques contenant un inhibiteur de pde4 et un inhibiteur de pi3 kinase delta ou un double inhibiteur de pi3 kinase delta et gamma
AU2013364070B2 (en) 2012-12-21 2016-10-27 Gilead Calistoga Llc Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
TW201441216A (zh) 2012-12-21 2014-11-01 Gilead Calistoga Llc 肌醇磷酯３－激酶的抑制劑
TR201806822T4 (tr) 2013-06-14 2018-06-21 Gilead Calistoga Llc Fosfatidilinositol 3-kinaz inhibitörleri.
CN104418849B (zh) * 2013-09-02 2020-04-21 广东东阳光药业有限公司 取代的氨基嘧啶类化合物及其使用方法和用途
EP3046921A4 (fr) * 2013-09-22 2017-02-22 Calitor Sciences, LLC Composés d'aminopyrimidine substituée et procédés d'utilisation
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
SG11201610770PA (en) 2014-07-04 2017-01-27 Lupin Ltd Quinolizinone derivatives as pi3k inhibitors
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
MX2017008076A (es) 2014-12-19 2018-01-09 Janssen Pharmaceutica Nv DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.
HUE045220T2 (hu) 2014-12-19 2019-12-30 Janssen Pharmaceutica Nv Imidazopiridazin-származékok mint PI3Kbéta inhibitorok
US9637488B2 (en) 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
UA122332C2 (uk) 2015-02-27 2020-10-26 Інсайт Корпорейшн Солі інгібітора pi3k і способи їх отримання
WO2016134668A1 (fr) * 2015-02-28 2016-09-01 Sunshine Lake Pharma Co., Ltd. Composés d'aminopyrimidine substituée et procédés d'utilisation
WO2016183060A1 (fr) 2015-05-11 2016-11-17 Incyte Corporation Procédé de synthèse d'un inhibiteur de phospho-inositide 3-kinases
WO2016183063A1 (fr) 2015-05-11 2016-11-17 Incyte Corporation Formes cristallines d'un inhibiteur de pi3k
JP6912460B2 (ja) 2015-10-09 2021-08-04 ヤンセン ファーマシューティカ エヌ．ベー． ＰＩ３Ｋβ阻害剤としてのキノキサリンおよびピリドピラジン誘導体
EP3404021A4 (fr) 2016-01-12 2019-09-11 Nippon Chemiphar Co., Ltd. Inhibiteur du canal calcique de type t tension-dépendant
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20190263804A1 (en) 2016-06-16 2019-08-29 Janssen Pharmaceutica Nv Azabenzimidazole derivatives as pi3k beta inhibitors
KR102472453B1 (ko) 2016-06-16 2022-11-29 얀센 파마슈티카 엔.브이. Pi3k 베타 저해제로서의 이환식 피리딘, 피라진, 및 피리미딘 유도체
MX2019000512A (es) 2016-07-12 2019-05-02 Bayer Cropscience Ag Compuestos biciclicos como plaguicidas.
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
EP3601254B1 (fr) 2017-03-29 2022-05-25 Janssen Pharmaceutica NV Dérivés de pyridopyrazine et de quinoxaline en tant qu'inhibiteurs de pi3k-beta
US20230190717A1 (en) * 2017-04-10 2023-06-22 City Of Hope P38 gamma inhibitors and method of use thereof
SG11202002032SA (en) 2017-09-22 2020-04-29 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
CA3076476A1 (fr) 2017-10-18 2019-04-25 Jubilant Epipad LLC Composes imidazo-pyridine a utiliser en tant qu'inhibiteurs de pad
BR112020008851A2 (pt) 2017-11-06 2020-10-20 Jubilant Prodel LLC composto da fórmula i, processo de preparação de compostos da fórmula i, composição farmacêutica, método para o tratamento e/ou prevenção de várias doenças, uso, método para o tratamento de câncer, método de tratamento de câncer e método para o tratamento e/ou prevenção de câncer e doenças infecciosas
PL3704120T3 (pl) 2017-11-24 2024-09-16 Jubilant Episcribe Llc Związki heterocykliczne jako inhibitory prmt5
BR122023024273A2 (pt) 2018-02-27 2024-02-20 Incyte Corporation Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
SG11202008950PA (en) 2018-03-13 2020-10-29 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
EP3810610A1 (fr) 2018-05-18 2021-04-28 Incyte Corporation Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
MX2020012826A (es) 2018-06-01 2021-03-09 Incyte Corp Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k).
AU2019297361B2 (en) 2018-07-05 2024-06-27 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
PY1960131A (es) 2018-08-07 2020-11-20 Syngenta Crop Protection Ag Compuestos heteroatomáticos bicíclicos activos como pesticidas
ES2974634T3 (es) 2018-12-21 2024-06-28 Celgene Corp Inhibidores de tienopiridinas de RIPK2
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
ES2995214T3 (en) 2019-03-06 2025-02-07 C4 Therapeutics Inc Heterocyclic compounds for medical treatment
GB201909190D0 (en) * 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
GB201909191D0 (en) * 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
CA3201690A1 (fr) 2020-12-15 2022-06-23 Children's Hospital Medical Center Composes multi-cycliques inhibiteurs d'irak et de flt3 et leurs utilisations
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
US20240254121A1 (en) 2021-05-06 2024-08-01 Bayer Aktiengesellschaft Alkylamide substituted, annulated imidazoles and use thereof as insecticides
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
AU2024264188A1 (en) * 2023-04-28 2025-11-06 Kurome Therapeutics, Inc. Irak inhibitor free base, salts, and polymorphic forms thereof
CN117466785B (zh) * 2023-11-02 2026-03-03 韶远科技（上海)有限公司 一种2-卤代-4-(甲基磺酰基)-1-硝基苯的制备方法
WO2026021573A1 (fr) * 2024-07-26 2026-01-29 InventisBio Co., Ltd. Composés, leurs procédés de préparation et leurs utilisations

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
CA1279648C (fr) * 1986-07-11 1991-01-29 Haruo Kuriyama Derives 2-(4-pyridylaminomethyl)benzimidazole a activite antivirale
EP0530149A1 (fr) * 1991-08-30 1993-03-03 Ciba-Geigy Ag Parasiticide
US6043062A (en) 1995-02-17 2000-03-28 The Regents Of The University Of California Constitutively active phosphatidylinositol 3-kinase and uses thereof
GB9611460D0 (en) 1996-06-01 1996-08-07 Ludwig Inst Cancer Res Novel lipid kinase
US5858753A (en) 1996-11-25 1999-01-12 Icos Corporation Lipid kinase
US5822910A (en) 1997-10-02 1998-10-20 Shewmake; I. W. Fishing line tensioning device
WO2003040141A1 (fr) * 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Composes d'oxazolyl-phenyl-2,4-diamino-pyrimidine, et methodes de traitement de troubles hyperproliferatifs
US7109337B2 (en) * 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
AR043692A1 (es) * 2003-02-06 2005-08-10 Novartis Ag 2-cianopirrolopirimidinas y sus usos farmaceuticos
GT200500284A (es) * 2004-10-15 2006-03-27 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
JP5291616B2 (ja) * 2006-04-26 2013-09-18 ジェネンテック， インコーポレイテッド ホスホイノシチド３−キナーゼ抑制剤化合物およびその使用方法
WO2008039882A1 (fr) * 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc Combinaison de niacine et d'un antagoniste du récepteur de prostaglandine d2
MX2010003449A (es) 2007-09-26 2010-04-27 Astellas Pharma Inc Derivado de quinolona.
EP2277881A4 (fr) * 2008-04-18 2011-09-07 Shionogi & Co Composé hétérocyclique présentant une activité inhibitrice sur p13k
GB0821693D0 (en) 2008-11-27 2008-12-31 Ucb Pharma Sa Therapeutic agents
EP2396315B1 (fr) 2009-02-13 2016-08-31 UCB Biopharma SPRL Dérivés de quinoline en tant qu'inhibiteurs de kinases pi3k
EA201270013A1 (ru) 2009-06-25 2012-06-29 Амген Инк. Гетероциклические соединения и их применение
MX2012006953A (es) 2009-12-18 2012-10-09 Amgen Inc Compuestos heterociclicos y sus usos.
US8759359B2 (en) * 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors

Also Published As

Publication number Publication date
MY184620A (en) 2021-04-09
MX2012011387A (es) 2013-02-26
TW201202219A (en) 2012-01-16
BR112012025164A2 (pt) 2016-06-21
US8575183B2 (en) 2013-11-05
SG184354A1 (en) 2012-11-29
JP2013540099A (ja) 2013-10-31
ZA201207341B (en) 2014-06-25
WO2011123751A3 (fr) 2014-08-07
CA2793897A1 (fr) 2011-10-06
TN2012000449A1 (en) 2014-01-30
IL222288A0 (en) 2012-12-31
EA201291005A1 (ru) 2013-09-30
AR081448A1 (es) 2012-09-05
US20110245257A1 (en) 2011-10-06
AU2011235031A1 (en) 2012-10-25
PH12012501922A1 (en) 2013-02-04
PE20130339A1 (es) 2013-04-13
CL2012002769A1 (es) 2013-07-05
CN103221403A (zh) 2013-07-24
EP2552908A2 (fr) 2013-02-06
AU2011235031B2 (en) 2014-10-23
WO2011123751A2 (fr) 2011-10-06
KR20130103309A (ko) 2013-09-23
CO6630161A2 (es) 2013-03-01
CR20120562A (es) 2013-03-01
UY33304A (es) 2011-10-31

Similar Documents

Publication Publication Date Title
EA201270013A1 (ru) Гетероциклические соединения и их применение
MA37472A1 (fr) Composés hétérocycliques et leurs utilisations
EA200901276A1 (ru) Гетероциклические соединения и их применение
EA201291005A1 (ru) Гетероциклические соединения и их применение
MX2009010050A (es) Derivados de quinolina o quinoxalina 3-sustituidos y su uso como inhibidores de fosfotidilinositol 3-cinasa (p13k).
MX2012015134A (es) Compuestos heterociclicos y su uso como inhibidores de actividad de pi3k.
WO2010151735A3 (fr) Composés hétérocycliques et leurs utilisations
MX2012015135A (es) Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.
MX2011013666A (es) Compuestos heterociclicos y sus usos.
WO2010151737A3 (fr) Composés hétérocycliques et leurs utilisations
TN2019000099A1 (fr) Anticorps anti-lag-3 et compositions
EP4480543A3 (fr) Macrocycle diaryle chiral et son utilisation dans le traitement du cancer
EP4275756A3 (fr) Dérivés de bipyrazole servant d'inhibiteurs de jak
MXPA05009595A (es) Compuestos 7-amino-isoindolilo y sus usos farmaceuticos.
UA96458C2 (ru) Тиазолпиразолопиримидиновые соединения как антагонисты рецептора crf1
EA201100524A1 (ru) Азаиндазолы в качестве антагонистов рецептора ccr1
PH12015502575B1 (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
WO2008022164A3 (fr) Composés de pyrazine, leur utilisation et procédés de préparation
PL1699800T3 (pl) Bicykliczne heterocykliczne inhibitory kinazy p-38
EA200970302A1 (ru) Тиофенпиразолопиримидиновые соединения
EP4467566A3 (fr) Bac d'anticorps de chimiokines elr+cxc
WO2020097568A3 (fr) Compositions oligosaccharidiques et leurs procédés d'utilisation
MXPA05003718A (es) Compuestos x-nitro, sus composiciones farmaceuticas y sus usos.
MX378799B (es) Combinación de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda.
ZA202100376B (en) Heterocyclic sulfonamide derivatives and pharmaceutical uses thereof